Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Daunorubicin (Daunomycin)

4 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    VICCHEM1654

    09/09/2016

    An Open-Label, Multi-Center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients with Newly Diagnosed FMS-Like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who are Eligible for Standard Induction and Consolidation Chemotherapy

    Treatment

    COGAAML1531

    08/23/2016

    Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

    Treatment

    VICCHEM15113

    05/06/2016

    A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation

    Treatment

    COGAALL1231

    05/13/2015

    A Phase III Randomized Trial Investigating Bortezomib NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)


    Print this page for your doctor